News for uniQure N.V. (QURE)

uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA […]

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

**media[643746]**

uniQure (QURE) aims for BLA submission for AMT-130 in Q1 2026, with support from FDA. AMT-130's trial will utilize the ENROLL-HD dataset of 33,000 patie

Chardan Capital has reaffirmed its Buy rating for uniQure (QURE), a biotechnology company noted for its innovative gene therapy solutions. This decision was rep

~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to

**media[640256]**

uniQure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs AMT-130’s BLA. See more on QURE here.

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ETCompany ParticipantsChiara Russo - Senior Director, Investor RelationsMatt...

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generall

**media[620252]**

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWS

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V. QURE rose sharply during Thursday's session afte...

Key Highlights: uniQure (QURE) revenue and earnings per share fell short of analyst expectations. The company's projected revenue growth outpaces the ind

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulator

uniQure (QURE) receives FDA Breakthrough Therapy designation for AMT-130, potentially accelerating regulatory approval for Huntington's disease treatment

**media[597939]**